Related Experiment Video

Updated: Apr 26, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.1K

Targeting MET Amplification as a New Oncogenic Driver

Hisato Kawakami1, Isamu Okamoto2, Wataru Okamoto3

  • 1Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. kawakami_h@dotd.med.kindai.ac.jp.

Cancers
|July 24, 2014
PubMed

Insights

Targeting MET amplification, a key driver in certain cancers, shows significant promise. Crizotinib demonstrates efficacy in preclinical models and clinical trials for MET-amplified cancers, supporting its role in precision medicine.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Many cancers rely on specific oncogenes for growth, a concept termed "oncogene addiction".
  • MET signaling pathway dysregulation, through amplification, mutation, or polysomy, drives a subset of advanced cancers.
  • Targeting driver oncogenes offers a promising avenue for precision cancer therapy.

Purpose of the Study:

  • To review the rationale for targeting MET amplification in cancer therapy.
  • To highlight MET amplification as an oncogenic driver.
  • To discuss the potential of MET inhibitors in treating MET-amplified cancers.

Main Methods:

  • Preclinical studies involving MET inhibition via crizotinib and RNA interference in MET-amplified cancer cell lines.
  • In vitro and in vivo experiments to assess antitumor effects.
  • Clinical evaluation of patient responses to crizotinib in MET-amplified non-small cell lung and gastric cancers.

Main Results:

  • Inhibition of MET signaling led to significant antitumor effects in MET-amplified cancer cell lines.
  • Patients with MET-amplified non-small cell lung cancer and gastric cancer showed marked clinical responses to crizotinib.
  • Crizotinib demonstrates clinical efficacy in genetically defined cancer patients with MET amplification.

Conclusions:

  • MET amplification is a validated oncogenic driver and a therapeutic target.
  • MET inhibitors like crizotinib show significant promise for treating MET-amplified cancers.
  • Further research is needed to determine the prevalence of MET amplification due to evaluation challenges.

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

22.8K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K